Atara Biotherapeutics, Inc. (0HIY.L)
USD 10.43
(-0.02%)
USD 10.43
(-0.02%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -276.12 Million USD | -20.95% |
| 2022 | -2.28 Billion USD | 32.88% |
| 2021 | -3.4 Billion USD | -10.93% |
| 2020 | -3.06 Billion USD | -5.38% |
| 2019 | -2.9 Billion USD | -26.13% |
| 2018 | -2.3 Billion USD | -93.07% |
| 2017 | -1.19 Billion USD | -51.16% |
| 2016 | -790.49 Million USD | -38.15% |
| 2015 | -572.21 Million USD | -104.32% |
| 2014 | -280.06 Million USD | -219.23% |
| 2013 | -87.73 Million USD | 28.85% |
| 2012 | -123.3 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -190.49 Million USD | 94.0% |
| 2024 Q1 | -317.52 Million USD | 47.47% |
| 2023 Q1 | -747.71 Million USD | -0.27% |
| 2023 FY | -2.76 Billion USD | -20.95% |
| 2023 Q4 | -604.5 Million USD | 13.39% |
| 2023 Q3 | -697.97 Million USD | 1.84% |
| 2023 Q2 | -711.08 Million USD | 4.9% |
| 2022 Q4 | -745.72 Million USD | 11.32% |
| 2022 Q1 | -881.05 Million USD | 5.62% |
| 2022 Q2 | 184.66 Million USD | 120.96% |
| 2022 FY | -2.28 Billion USD | 32.88% |
| 2022 Q3 | -840.91 Million USD | -555.38% |
| 2021 Q3 | -846.64 Million USD | -1.04% |
| 2021 Q4 | -933.49 Million USD | -10.26% |
| 2021 Q1 | -783.35 Million USD | 3.66% |
| 2021 FY | -3.4 Billion USD | -10.93% |
| 2021 Q2 | -837.93 Million USD | -6.97% |
| 2020 Q4 | -813.07 Million USD | -9.36% |
| 2020 Q1 | -735.09 Million USD | 6.35% |
| 2020 Q2 | -774.56 Million USD | -5.37% |
| 2020 Q3 | -743.48 Million USD | 4.01% |
| 2020 FY | -3.06 Billion USD | -5.38% |
| 2019 Q2 | -743.28 Million USD | -12.18% |
| 2019 Q1 | -662.57 Million USD | 17.19% |
| 2019 FY | -2.9 Billion USD | -26.13% |
| 2019 Q4 | -784.96 Million USD | -9.18% |
| 2019 Q3 | -718.95 Million USD | 3.27% |
| 2018 Q3 | -583.61 Million USD | -14.7% |
| 2018 Q1 | -414.43 Million USD | -17.36% |
| 2018 FY | -2.3 Billion USD | -93.07% |
| 2018 Q4 | -800.12 Million USD | -37.1% |
| 2018 Q2 | -508.83 Million USD | -22.78% |
| 2017 Q1 | -256.54 Million USD | -40.69% |
| 2017 FY | -1.19 Billion USD | -51.16% |
| 2017 Q4 | -353.13 Million USD | -13.56% |
| 2017 Q3 | -310.96 Million USD | -13.37% |
| 2017 Q2 | -274.28 Million USD | -6.92% |
| 2016 Q2 | -188.8 Million USD | -14.0% |
| 2016 Q1 | -165.61 Million USD | 22.06% |
| 2016 FY | -790.49 Million USD | -38.15% |
| 2016 Q4 | -182.35 Million USD | 28.13% |
| 2016 Q3 | -253.73 Million USD | -34.39% |
| 2015 FY | -572.21 Million USD | -104.32% |
| 2015 Q2 | -149.45 Million USD | -63.16% |
| 2015 Q1 | -91.6 Million USD | 12.99% |
| 2015 Q4 | -212.48 Million USD | -79.04% |
| 2015 Q3 | -118.68 Million USD | 20.59% |
| 2014 Q2 | -45.11 Million USD | 36.01% |
| 2014 Q4 | -105.27 Million USD | -77.85% |
| 2014 FY | -280.06 Million USD | -219.23% |
| 2014 Q3 | -59.19 Million USD | -31.21% |
| 2014 Q1 | -70.49 Million USD | -98.23% |
| 2013 Q1 | -12.98 Million USD | 0.0% |
| 2013 Q3 | -25.36 Million USD | -83.37% |
| 2013 Q4 | -35.56 Million USD | -40.22% |
| 2013 FY | -87.73 Million USD | 28.85% |
| 2013 Q2 | -13.83 Million USD | -6.55% |
| 2012 FY | -123.3 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | -80.217% |
| Dynavax Technologies Corporation | -6.38 Million USD | -4221.897% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 21082.219% |
| Perrigo Company plc | -12.7 Million USD | -2074.22% |
| Illumina, Inc. | -1.16 Billion USD | 76.217% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 104.606% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 37.815% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 96.803% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 120.333% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -149.754% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 106.984% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -592.74% |
| Waters Corporation | 642.23 Million USD | 142.995% |
| Biogen Inc. | 1.16 Billion USD | 123.781% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | -7.096% |
| Evolus, Inc. | -61.68 Million USD | -347.639% |
| Adicet Bio, Inc. | -142.65 Million USD | -93.558% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -132.992% |
| bluebird bio, Inc. | -211.91 Million USD | -30.302% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | -31.961% |
| FibroGen, Inc. | -284.23 Million USD | 2.852% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 122.268% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -519.071% |
| Homology Medicines, Inc. | -53.74 Million USD | -413.79% |
| Geron Corporation | -184.12 Million USD | -49.965% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 37.279% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | -82.16% |
| Myriad Genetics, Inc. | -112 Million USD | -146.541% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -221.469% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 42.616% |
| Zoetis Inc. | 2.34 Billion USD | 111.78% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -409.57% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 135.007% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 264.709% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 107.629% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -554.343% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 24.615% |
| Verastem, Inc. | -87.36 Million USD | -216.053% |
| Nektar Therapeutics | -276.05 Million USD | -0.025% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | -15.419% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -212.074% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 48.482% |
| OPKO Health, Inc. | -188.86 Million USD | -46.204% |
| Exelixis, Inc. | 207.76 Million USD | 232.903% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 210.583% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 360.153% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -481.257% |
| uniQure N.V. | -308.47 Million USD | 10.488% |
| Imunon, Inc. | -19.51 Million USD | -1314.944% |
| Blueprint Medicines Corporation | -506.98 Million USD | 45.536% |
| Insmed Incorporated | -749.56 Million USD | 63.162% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 198.058% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 21.575% |
| TG Therapeutics, Inc. | 12.67 Million USD | 2279.025% |
| Incyte Corporation | 597.59 Million USD | 146.206% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 63.692% |